No profile data available.
Oruka Therapeutics, Inc. (ORKA) is a healthcare company in the skin treatment pharmaceuticals industry, based in Menlo Park, United States, with about 68 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$105.43 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $5.44 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.
Oruka Therapeutics reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$5.44 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (skin treatment pharmaceuticals) include Krystal Biotech, Inc. (KRYS), Kymera Therapeutics, Inc. (KYMR), Arcutis Biotherapeutics, Inc. (ARQT), Almirall, S.a. (ALMRY).